Regadenoson (BioDeep_00000743400)

   


代谢物信息卡片


Regadenoson

化学式: C15H18N8O5 (390.14000980000003)
中文名称: 瑞加德松
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N
InChI: InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1

描述信息

D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
C - Cardiovascular system > C01 - Cardiac therapy
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS[1][2].
Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS[1][2].

同义名列表

2 个代谢物同义名

Regadenoson; CVT-3146



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Dun-Jian Wang, Da-Wei Wang, Qiu-Chen Fang, Ye Shen, Nv-Jin Zeng, Yan-Ling Yang, Hong-Wen Zhang, Yong-Qing Wang, Lu-Ning Sun. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the quantification of regadenoson in human plasma and its pharmacokinetic application. Journal of separation science. 2022 Mar; 45(6):1146-1152. doi: 10.1002/jssc.202100756. [PMID: 34981883]
  • Ahmed A Kolkailah, Mina Iskander, Fady Iskander, Priya P Patel, Rozi Khan, Rami Doukky. The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2022 Feb; 29(1):101-110. doi: 10.1007/s12350-020-02259-1. [PMID: 32632913]
  • Christine L Lau, Jared P Beller, Joshua A Boys, Yunge Zhao, Jennifer Phillips, Michael Cosner, Mark R Conaway, Gina Petroni, Eric J Charles, J H Mehaffey, Hannah C Mannem, Irving L Kron, Alexander S Krupnick, Joel Linden. Adenosine A2A receptor agonist (regadenoson) in human lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2020 06; 39(6):563-570. doi: 10.1016/j.healun.2020.02.003. [PMID: 32503727]
  • Danai Kitkungvan, Linh Bui, Nils P Johnson, Monica B Patel, Amanda E Roby, Pimprapa Vejpongsa, Asim K Babar, Mohammad Madjid, Angelo Nacimbene, Sachin Kumar, Alexandra DeGolovine, K Lance Gould. Quantitative myocardial perfusion positron emission tomography and caffeine revisited with new insights on major adverse cardiovascular events and coronary flow capacity. European heart journal. Cardiovascular Imaging. 2019 Jul; 20(7):751-762. doi: 10.1093/ehjci/jez080. [PMID: 31056681]
  • Ankur Gupta, Navkaranbir S Bajaj. Regadenoson use for stress myocardial perfusion imaging in advance chronic kidney disease and dialysis: Safe, effective, and efficient. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2018 02; 25(1):150-152. doi: 10.1007/s12350-017-1038-1. [PMID: 28808896]
  • Aviral Vij, Yasmeen Golzar, Rami Doukky. Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2018 02; 25(1):137-149. doi: 10.1007/s12350-017-0960-6. [PMID: 28653271]
  • Sadhana Jackson, Jon Weingart, Edjah K Nduom, Thura T Harfi, Richard T George, Dorothea McAreavey, Xiaobu Ye, Nicole M Anders, Cody Peer, William D Figg, Mark Gilbert, Michelle A Rudek, Stuart A Grossman. The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids and barriers of the CNS. 2018 Jan; 15(1):2. doi: 10.1186/s12987-017-0088-8. [PMID: 29332604]
  • Erica O Miller, Ronald G Schwartz. Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: Does it matter?. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2017 02; 24(1):119-121. doi: 10.1007/s12350-015-0337-7. [PMID: 26626782]
  • Rami Doukky, Ibtihaj Fughhi, Tania Campagnoli, Marwan Wassouf, Amjad Ali. The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2017 02; 24(1):112-118. doi: 10.1007/s12350-015-0303-4. [PMID: 26582040]
  • Robert Townsend, Amit Desai, Diane Rammelsberg, Donna Kowalski, Neal Simmons, Therese M Kitt. Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2017 02; 24(1):57-65. doi: 10.1007/s12350-015-0327-9. [PMID: 26607361]
  • Wael AlJaroudi, Tania Campagnoli, Ibtihaj Fughhi, Marwan Wassouf, Amjad Ali, Rami Doukky. Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2016 06; 23(3):560-9. doi: 10.1007/s12350-015-0234-0. [PMID: 26293358]
  • Sadhana Jackson, Nicole M Anders, Antonella Mangraviti, Teresia M Wanjiku, Eric W Sankey, Ann Liu, Henry Brem, Betty Tyler, Michelle A Rudek, Stuart A Grossman. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. Journal of neuro-oncology. 2016 Feb; 126(3):433-9. doi: 10.1007/s11060-015-1998-4. [PMID: 26626489]
  • Heidi L Brink, Jennifer A Dickerson, Julie A Stephens, Kerry K Pickworth. Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing. Pharmacotherapy. 2015 Dec; 35(12):1117-23. doi: 10.1002/phar.1669. [PMID: 26684552]
  • Maria Octavia Rangel, Raysa Morales Demori, Sarah T Voll, Marwan Wassouf, Rizcallah Dick, Rami Doukky. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2015 Oct; 22(5):1008-18. doi: 10.1007/s12350-014-0036-9. [PMID: 25500799]
  • Sabha Bhatti, Abdul Hakeem, Sunitha Dhanalakota, Gurunanthan Palani, Zehra Husain, Gordon Jacobsen, Karthik Ananthasubramaniam. Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunction. European heart journal. Cardiovascular Imaging. 2014 Aug; 15(8):933-40. doi: 10.1093/ehjci/jeu036. [PMID: 24699324]
  • Federico Caobelli, Frank M Bengel. Further evidence for the robustness of regadenoson stress myocardial perfusion SPECT: its predictive value for cardiac events in chronic renal failure. European heart journal. Cardiovascular Imaging. 2014 Aug; 15(8):941-2. doi: 10.1093/ehjci/jeu056. [PMID: 24714138]
  • Sahar S Abdelmoneim, Mary E Hagen, Edward Mendrick, Vishwanath Pattan, Benjamin Wong, Barbara Norby, Tamara Roberson, Troy Szydel, Rita Basu, Ananda Basu, Sharon L Mulvagh. Acute hyperglycemia reduces myocardial blood flow reserve and the magnitude of reduction is associated with insulin resistance: a study in nondiabetic humans using contrast echocardiography. Heart and vessels. 2013 Nov; 28(6):757-68. doi: 10.1007/s00380-012-0305-y. [PMID: 23180239]
  • Rami Doukky, Maria Octavia Rangel, Rizcallah Dick, Marwan Wassouf, Ammar Alqaid, Bosko Margeta. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial. The international journal of cardiovascular imaging. 2013 Jun; 29(5):1029-37. doi: 10.1007/s10554-012-0166-6. [PMID: 23224354]
  • Rami Doukky, Maria Octavia Rangel, Marwan Wassouf, Rizcallah Dick, Ammar Alqaid, Raysa Morales Demori. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2013 Apr; 20(2):205-13. doi: 10.1007/s12350-012-9654-2. [PMID: 23239416]
  • Ami E Iskandrian, Fadi G Hage, Jaekyeong Heo. Use of regadenoson in end-stage renal disease. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2013 Apr; 20(2):182-4. doi: 10.1007/s12350-012-9658-y. [PMID: 23225540]
  • Gopal Ghimire, Fadi G Hage, Jaekyeong Heo, Ami E Iskandrian. Regadenoson: a focused update. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2013 Apr; 20(2):284-8. doi: 10.1007/s12350-012-9661-3. [PMID: 23229649]
  • Anil Pandit, Samuel Unzek Freiman. Complete heart block associated with regadenoson: a real side effect. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2012 Dec; 19(6):1236-9. doi: 10.1007/s12350-012-9610-1. [PMID: 22915132]
  • Xiaocheng Zhu, Hiroaki Shiba, John J Fung, Lian-Fu Wang, Yusuke Arakawa, Samuel Irefin, Anthony J Demetris, Dympna M Kelly. The role of the A2a receptor agonist, regadenoson, in modulating hepatic artery flow in the porcine small-for-size liver graft. The Journal of surgical research. 2012 May; 174(1):e37-45. doi: 10.1016/j.jss.2011.10.003. [PMID: 22225980]
  • Karthik Ananthasubramaniam, Robert Weiss, Bruce McNutt, Barbara Klauke, Kathleen Feaheny, Stan Bukofzer. A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2012 Apr; 19(2):319-29. doi: 10.1007/s12350-011-9508-3. [PMID: 22259009]
  • G M Bengalorkar, K Bhuvana, N Sarala, T N Kumar. Regadenoson. Journal of postgraduate medicine. 2012 Apr; 58(2):140-6. doi: 10.4103/0022-3859.97177. [PMID: 22718059]
  • Francesca Deflorian, T Santhosh Kumar, Khai Phan, Zhan-Guo Gao, Fei Xu, Huixian Wu, Vsevolod Katritch, Raymond C Stevens, Kenneth A Jacobson. Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor. Journal of medicinal chemistry. 2012 Jan; 55(1):538-52. doi: 10.1021/jm201461q. [PMID: 22104008]
  • Fadi G Hage, Phillip Dean, Fahad Iqbal, Jaekyeong Heo, Ami E Iskandrian. A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2011 Dec; 18(6):1086-94. doi: 10.1007/s12350-011-9429-1. [PMID: 21785922]
  • Eliana Reyes, Peter Staehr, Ann Olmsted, Dewan Zeng, Brent Blackburn, Manuel D Cerqueira, S Richard Underwood. Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2011 Aug; 18(4):620-7. doi: 10.1007/s12350-011-9377-9. [PMID: 21553161]
  • Gurunanthan Palani, Zehra Husain, Rafael Cabrera Salinas, Vanji Karthikeyan, Aarthee S Karthikeyan, Karthik Ananthasubramaniam. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2011 Aug; 18(4):605-11. doi: 10.1007/s12350-011-9378-8. [PMID: 21541818]
  • Wael Aljaroudi, Daniel Hermann, Fadi Hage, Jaekyeong Heo, Ami E Iskandrian. Safety of regadenoson in patients with end-stage renal disease. The American journal of cardiology. 2010 Jan; 105(1):133-5. doi: 10.1016/j.amjcard.2009.08.663. [PMID: 20102905]
  • Saaron Laighold, Regina Druz. Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2009 May; 16(3):478-80. doi: 10.1007/s12350-008-9043-z. [PMID: 19159989]
  • Toufigh Gordi, Brent Blackburn, Hsiao Lieu. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. Journal of clinical pharmacology. 2007 Jul; 47(7):825-33. doi: 10.1177/0091270007301620. [PMID: 17585115]
  • Kenneth A Jacobson, Zhan-Guo Gao. Adenosine receptors as therapeutic targets. Nature reviews. Drug discovery. 2006 Mar; 5(3):247-64. doi: 10.1038/nrd1983. [PMID: 16518376]
  • Arvinder K Dhalla, Mei-Yee Wong, Wei-Qun Wang, Italo Biaggioni, Luiz Belardinelli. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. The Journal of pharmacology and experimental therapeutics. 2006 Feb; 316(2):695-702. doi: 10.1124/jpet.105.095323. [PMID: 16227469]
  • Toufigh Gordi, Paul Frohna, Hai-Ling Sun, Andrew Wolff, Luiz Belardinelli, Hsiao Lieu. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clinical pharmacokinetics. 2006; 45(12):1201-12. doi: 10.2165/00003088-200645120-00005. [PMID: 17112296]
  • Gong Zhao, Axel Linke, Xiaobin Xu, Manuel Ochoa, Francis Belloni, Luiz Belardinelli, Thomas H Hintze. Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs. The Journal of pharmacology and experimental therapeutics. 2003 Oct; 307(1):182-9. doi: 10.1124/jpet.103.053306. [PMID: 12954805]